<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12B-25
---------------------------
SEC FILE NUMBER
0-9065
---------------------------
NOTIFICATION OF LATE FILING
---------------------------
CUSIP NUMBER
38114510 1
---------------------------
(Check One): [ ] Form 10-K [ ] Form 20-F
[ ] Form 11-K [X] Form 10-Q
[ ] Form N-SAR
For Period Ended: February 28, 1999
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
-------------------------------
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
- -------------------------------------------------------------------------------
PART I - REGISTRANT INFORMATION
Golden Pharmaceuticals, Inc.
- -------------------------------------------------------------------------------
Full Name of Registrant
- -------------------------------------------------------------------------------
Former Name if Applicable
3000 W. Warner Avenue
- -------------------------------------------------------------------------------
Address of Principal Executive Office (Street and Number)
Santa Ana, California 92704
- -------------------------------------------------------------------------------
City, State and Zip Code
<PAGE> 2
PART II - RULES 12B-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following
should be completed. (Check appropriate box)
[X] (a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or
expense;
[X] (b) The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion
thereof, will be filed on or before the fifteenth calendar day
following the prescribed due date; or the subject quarterly
report of transition report on Form 10-Q, or portion thereof will
be filed on or before the fifth calendar day following the
prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III - NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q,
N-SAR, or the transition report or portion thereof, could not be filed within
the prescribed time period.
The Registrant is unable to timely complete the information required for the
presentation of its Quarterly Report on Form 10-Q for the period ended February
28, 1999 due to the negotiation and closing of a financing transaction with Alco
Financial Services, LLC to, among other things, replace an outstanding loan with
Norwest Credit, Inc.
<PAGE> 3
PART IV - OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
John H. Grant (714) 754-5800
--------------------------- ----------- ------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that
the registrant was required to file such report(s) been filed? If answer
is no, identify report(s). [X] Yes [ ] No
- -------------------------------------------------------------------------------
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected
by the earnings statements to be included in the subject report or portion
thereof? [ ] Yes [X] No
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
===============================================================================
Golden Pharmaceuticals, Inc.
---------------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date April 15, 1999 By /s/ John H. Grant
------------------- --------------------------------------
John H. Grant, Chief Operating Officer
